This announcement contains inside
information as stipulated under the UK version of the
Market Abuse Regulation No 596/2014 which is part of English law by
virtue of the European (Withdrawal) Act 2018, as amended. On
publication of this announcement via a regulatory information
service, this information is considered to be in the public
domain.
6 March
2025
EDX Medical Group
plc
AQSE: EDX
("EDX Medical" or the "Group"
or "Company")
EDX MEDICAL SIGNS MASTER
SERVICES AGREEMENT WITH
THE ROYAL MARSDEN NHS
FOUNDATION TRUST
CAMBRIDGE, UK: EDX Medical
Group plc, which develops innovative digital diagnostic
products and services supporting personalised treatments for
cancer, cardiovascular disease and infectious
diseases, announces today it has signed a master service
agreement with The Royal Marsden NHS Foundation Trust ("The Royal
Marsden").
Under the terms of the three-year
agreement, EDX Medical will, as required, supply services to The
Royal Marsden.
Professor Sir Chris Evans, founder and chief scientific
officer of EDX Medical, commented: "I have always had the highest regard for the people and the
work they do at The Royal Marsden and have run some significant
cancer clinical trials there over the years. I am delighted EDX
Medical has now been appointed as a supplier of diagnostic
solutions and services to help serve the needs of one of the
world's most eminent cancer hospitals."
The Board of directors of EDX
Medical plc accepts responsibility for this
announcement.
ENDS
Contacts
|
EDX
Medical Group Plc
|
|
|
Dr Mike Hudson (Chief
Executive Officer)
|
+44 (0)7812 345 301
|
|
|
|
|
Oberon Capital
|
|
|
Nick Lovering (Corporate
Adviser)
Adam Pollock (Corporate
Broking)
Mike Seabrook (Corporate
Broking)
|
+44 (0)20 3179 5300
|
|
|
|
|
Media House International
|
|
|
Ramsay Smith
Gary McQueen
|
+44 (0)7788 414856
ramsay@mediahouse.co.uk
+ 44 (0)7834 694609
gary@mediahouse.co.uk
|
|
|
|
|
IFC
Advisory (Investor Relations)
|
|
|
Tim Metcalfe
Graham Herring
|
+44 (0)20 3934 6630
|
Notes for
Editors:
About EDX Medical Group plc
The EDX Medical
Group plc is listed on the Apex Segment of the AQSE
Growth Market (TIDM: EDX).
EDX Medical was founded by
Professor Sir Christopher Evans, OBE, a medical and life
sciences entrepreneur with more than 30 years of experience,
together with CEO, Dr Mike Hudson.
By translating clinical insights
into pragmatic solutions combining advanced biological and digital
technologies, EDX Medical seeks to cost effectively improve the
detection and characterisation of disease in order to personalise
treatment in a timely fashion. Early disease detection and
biologically-based personal treatment optimisation is considered to
be the most impactful way of improving patient outcomes, reducing
deaths and lowering the cost of healthcare globally.
EDX Medical Group provides
doctors, hospitals and insurers/payers with access to a portfolio
of the best clinical diagnostics products and services. The Company
operates its own facilities in Cambridge and Oxford,
UK, and has strategic product and technology partnerships with
organisations such as Thermo Fisher EMEA Ltd, a world leader
in supplying life sciences solutions and services.
EDX Medical conducts product
development, validation and distribution to ISO 13485 and provides
PCR services accredited to ISO 15189 by the United Kingdom
Accreditation Service (UKAS).
www.edxmedical.com
